A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
Status:
Withdrawn
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates a new test formulation of a glucose lowering drug, insulin lispro,
delivered by an insulin pump continuously under the skin. The study will be conducted in
participants with type 1 diabetes mellitus to investigate how the human body processes the
new test formulation and its effect on blood sugar levels when it is delivered via an insulin
pump. Side effects and tolerability will be documented. The study will last about 4 to 11
weeks, including screening, lead-in and follow up. Screening is required within 28 days prior
to entering the study.